LB Pharmaceuticals Inc.

LBRX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001691082


None

No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $312.9M
Warnings	thin data not computable: dilution, degenerate inputs, fortress balance sheet
Inputs computable	2 of 14
Graded from	filings received through Mar 26, 2026 225 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$38.13 2026-11-05; market equity $1.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

We are a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	not computable	(6.6%)				
a prior annual assets observation is required						
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 10.6						
Twelve-month failure probability	0.04%	0.07%		20.6	249	2026-09-30
Altman Z double-prime	not computable	(0.37)				
one or more required annual facts are missing						
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	41.44x	2.94x		0.6	828	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.0%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 1						
Net share issuance, one year	not computable	2.5%				
two annual share counts are required; found 1						

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	2 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	137.9%	(2.1%)	94
Distance from 52-week high	(23.0%)	(30.4%)	58
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(2.9%)	(1.0%)	45
Book value to price	0.34	0.29	56
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	0.70	(0.19)	94

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$215.1M
Operating cash flow, four quarters	-$143.3M
Months of runway	18.0
Days since last periodic filing	1 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$13.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$25.2M	2025-12-31	2026-03-26	10-K	26-126368
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$35.2M	2025-12-31	2026-03-26	10-K	26-126368
3	assets	us-gaap:Assets	$312.9M	2025-12-31	2026-03-26	10-K	26-126368
4	current assets	us-gaap:AssetsCurrent	$308.4M	2025-12-31	2026-03-26	10-K	26-126368
5	current liabilities	us-gaap:LiabilitiesCurrent	$7.4M	2025-12-31	2026-03-26	10-K	26-126368
6	shares outstanding	dei:EntityCommonStockSharesOutstanding	28,674,827	2026-03-23	2026-03-26	10-K	26-126368

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.